Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Molecularly targeted kinase inhibitor cancer therapies are currently administered sequentially rather than simultaneously. We addressed the potential long-term impact of this strategy in patients with chronic myelogenous leukemia (CML), which is driven by the fusion oncogene BCR-ABL. Analysis of BCR...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Shah, Neil P., Skaggs, Brian J., Branford, Susan, Hughes, Timothy P., Nicoll, John M., Paquette, Ronald L., Sawyers, Charles L.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society for Clinical Investigation 2007
Témata:
Research Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC1940237/
https://ncbi.nlm.nih.gov/pubmed/17710227
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI30890
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky